Your current web browser is outdated. For best viewing experience, please consider upgrading to the latest version.

Donation - Other Level

Please use the quantity box to donate any amount you wish. Sign Up to Donate


Send a question or comment using the form below. This message may be routed through support staff.

Email Article

Password Reset Request


Add a topic or expert to your feed.


Follow Experts & Topics

Stay on top of our work by selecting topics and experts of interest.

On The Ground
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed

Manhattan Institute

Close Nav
Share this commentary on Close

Paul Howard Departs MI for FDA


Paul Howard Departs MI for FDA

December 15, 2017
Health PolicyFDA Reform

Paul Howard was formerly a senior fellow and director of health policy at the Manhattan Institute. In December 2017, he joined the U.S. Food Drug Administration as Senior Advisor to the Commissioner of the FDA.

During his tenure at the Manhattan Institute, Howard has supplied exemplary research and analysis of America’s sprawling and often bewildering health care system. In the process, he has elevated the public discourse on a vast array of health-care issues, ranging from FDA reform, biopharmaceutical innovation, consumer-driven health care, to Medicare and Medicaid reform.

He has been a prolific writer on the subject of health care, with his work appearing in such publications as Bloomberg View, New York TimesWall Street JournalNational AffairsUSA Today, RealClearPolitics, New York PostInvestor’s Business DailyHealth Affairs, and Along with Peter Huber, he was the co-author of Unlocking Precision Medicine (Encounter Books, 2016). He was a founding member of MI’s Project FDA.

Howard was part of the health-care policy advisory group for Mitt Romney’s 2012 presidential campaign, has testified four times before Congress, and, during 2013–17, served on an expert panel as a judge for Celgene’s Innovation Impact Awards. He joined MI in 2000, as deputy director of its Center for Legal Policy. He holds a B.A. from the College of the Holy Cross and a Ph.D. in political philosophy from Fordham University.

Howard leaves at a propitious time for the field of medical innovation. We invite you to join us in congratulating Paul on his achievements to date, and to wish him well in all his future endeavors.